Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder involving the nervous system, caused by a heterozygous mutation of the NF1 tumor suppressor gene on chromosome 17. It affects approximately 1 in 2,500 to 3,000 individuals, with an equal sex distribution [1]. As implied by the name of the disease, neurofibroma development is one of its major clinical features. Neurofibromas are tumors of peripheral nerve sheath origin. They can appear in any part of the body, with variable clinical and pathological manifestations. Generally, their presentations range from the most common localized forms to complex diffuse or plexiform types [2]. Moreover, a rare malignant form also exists, characterized by tumors known as malignant peripheral nerve sheath tumors. Otherwise, neurofibromas are basically benign tumors, although they can arise virtually anywhere that nervous tissue exists and cause sensory or motor symptoms. In some cases, significant morbidity or even death occurs, depending on the location or tumor burden. Even in cases without considerable morbidity, the disfigurement caused by multiple cutaneous neurofibromas or a few huge plexiform neurofibromas can cause profound distress to the individuals affected.